BlackRock Inc. lifted its stake in shares of Agenus Inc (NASDAQ:AGEN) by 15.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,717,966 shares of the biotechnology company’s stock after acquiring an additional 776,715 shares during the quarter. BlackRock Inc. owned approximately 5.50% of Agenus worth $12,980,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. A.R.T. Advisors LLC bought a new position in shares of Agenus during the 1st quarter valued at approximately $103,000. Russell Investments Group Ltd. bought a new position in shares of Agenus during the 1st quarter valued at approximately $197,000. Barclays PLC grew its stake in shares of Agenus by 95.8% during the 1st quarter. Barclays PLC now owns 73,955 shares of the biotechnology company’s stock valued at $348,000 after acquiring an additional 36,179 shares during the period. UBS Group AG grew its stake in shares of Agenus by 1,180.3% during the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock valued at $647,000 after acquiring an additional 126,684 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Agenus by 9.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock valued at $870,000 after acquiring an additional 34,065 shares during the period. Institutional investors own 35.39% of the company’s stock.
NASDAQ AGEN opened at $1.59 on Thursday. Agenus Inc has a 12 month low of $1.54 and a 12 month high of $6.19. The company has a market capitalization of $194.85 million, a P/E ratio of -1.29 and a beta of 1.83.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.16. As a group, analysts anticipate that Agenus Inc will post -1.2 earnings per share for the current year.
Separately, Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
See Also: Technical Analysis
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.